Business UpdateMay 14, 2026, 08:02 AM
CVRx Barostim Therapy Receives Humana Medicare Advantage Coverage
AI Summary
CVRx, Inc. announced that Humana has issued a Medicare Advantage coverage policy for its Barostim therapy, effective May 1, 2026. This policy, the first of its kind for Barostim, covers patients meeting the FDA-approved indication and those enrolled in the BENEFIT-HF trial, significantly expanding access to the therapy for heart failure patients. This development follows other positive reimbursement news this year, including Category I CPT codes and CMS approval of Category B IDE coverage for the BENEFIT-HF trial.
Key Highlights
- Humana issued Medicare Advantage coverage policy for CVRx's Barostim therapy, effective May 1, 2026.
- Humana covers approximately 5.2 million Medicare Advantage members across 46 states.
- The policy covers Barostim for its FDA-approved indication and patients in the BENEFIT-HF trial.
- This is the first Medicare Advantage coverage policy for Barostim therapy.
- Follows Category I CPT codes for Barostim procedure effective January 1, 2026.
- Follows CMS approval of Category B IDE coverage for BENEFIT-HF trial patients in January 2026.